Lymphomatoid Granulomatosis (LYG)

Categories: Blood diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphomatoid Granulomatosis

MalaCards integrated aliases for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 19 58 75 53 36 71 33
Granulomatosis, Lymphomatoid 75
Lyg 58


Age Of Onset:

Adult 58


Orphanet: 58  
Rare haematological diseases

External Ids:

MESH via Orphanet 44 D008230
ICD10 via Orphanet 32 C83.8
UMLS via Orphanet 72 C0024307
Orphanet 58 ORPHA86869
ICD11 33 1890408959
UMLS 71 C0024307

Summaries for Lymphomatoid Granulomatosis

GARD: 19 Lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as B lymphocytes. These B cells can build up in the tissues of the body, causing damage to the blood vessels. In many cases of Lymphomatoid granulomatosis, the abnormal B cells contain the Epstein-Barr virus. The disease is more common in men, usually after the fifth decade of life. Lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. Signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. Skin lesions and central nervous system changes such as headaches, seizures, and ataxia may also be seen. Rarely, the disorder can affect the kidneys or liver. The cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part.

MalaCards based summary: Lymphomatoid Granulomatosis, also known as granulomatosis, lymphomatoid, is related to lymphoproliferative syndrome, x-linked, 1 and acquired immunodeficiency syndrome, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Allograft rejection. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, spleen and liver, and related phenotypes are immune system and hematopoietic system

Orphanet: 58 Lymphomatoid granulomatosis (LYG) is a very rare Epstein-Barr virus (EBV)-driven lymphoproliferative disease most commonly occurring in adults (in the fourth to sixth decade of life) and commonly affecting the lungs (with presentations varying from small bilateral pulmonary nodules to large necrotic and sometimes cavitating lesions), skin, central nervous system, and kidneys, but only very rarely affecting the lymph nodes and spleen. The symptoms associated with LYG depend on the site of disease involvement but mainly include cough, dyspnea or chest pain (in those with pulmonary involvement) and constitutional symptoms such as weight loss and fever.

Wikipedia: 75 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Related Diseases for Lymphomatoid Granulomatosis

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 lymphoproliferative syndrome, x-linked, 1 31.8 TIA1 GZMB
2 acquired immunodeficiency syndrome 30.4 IFNA2 IFNA1
3 nasal type extranodal nk/t-cell lymphoma 30.4 TIA1 GZMB
4 splenomegaly 30.3 IFNA2 IFNA1
5 lethal midline granuloma 30.2 TIA1 GZMB
6 viral infectious disease 30.0 IFNA2 IFNA1 GZMB
7 kaposi sarcoma 29.9 IFNA2 IFNA1
8 peripheral t-cell lymphoma 29.9 TIA1 GZMB
9 panniculitis 29.8 TIA1 GZMB
10 mature t-cell and nk-cell lymphoma 29.8 TIA1 GZMB
11 alopecia areata 29.8 GZMB CXCL9
12 celiac disease 1 29.2 TIA1 IFNA1 GZMB
13 malaria 29.1 IFNA2 IFNA1 GZMB CXCL9
14 primary cutaneous t-cell non-hodgkin lymphoma 28.9 TIA1 IFNA2 IFNA1 GZMB
15 mycosis fungoides 28.5 TIA1 IFNA2 IFNA1 GZMB CXCL9
16 lymphoproliferative syndrome 1 11.4
17 primary pulmonary lymphoma 11.2
18 lymphoproliferative syndrome 10.9
19 vasculitis 10.7
20 b-cell lymphoma 10.7
21 diffuse large b-cell lymphoma 10.5
22 immune deficiency disease 10.5
23 sarcoidosis 1 10.4
24 sarcoidosis 2 10.4
25 lymphoma 10.4
26 respiratory failure 10.4
27 polymorphic reticulosis 10.4
28 rheumatoid arthritis 10.4
29 exanthem 10.4
30 granulomatosis with polyangiitis 10.3
31 lymphoma, hodgkin, classic 10.3
32 sjogren syndrome 10.3
33 burkitt lymphoma 10.2
34 aplastic anemia 10.2
35 human immunodeficiency virus type 1 10.2
36 leukemia, acute lymphoblastic 10.2
37 pancytopenia 10.2
38 brain cancer 10.2
39 pneumonia 10.2
40 lymphatic system disease 10.2
41 neuropathy 10.2
42 post-transplant lymphoproliferative disease 10.2
43 functional neutrophil defect 10.2
44 leukemia, chronic lymphocytic 10.2
45 hemophagocytic lymphohistiocytosis, familial, 1 10.2
46 agammaglobulinemia, x-linked 10.2
47 wiskott-aldrich syndrome 10.2
48 leukemia, acute myeloid 10.2
49 aphasia 10.2
50 agammaglobulinemia 10.2

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:

Diseases related to Lymphomatoid Granulomatosis

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

UMLS symptoms related to Lymphomatoid Granulomatosis:

fever; malaise

MGI Mouse Phenotypes related to Lymphomatoid Granulomatosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.35 CXCL9 GZMB IFNA1 IFNA2 TIA1
2 hematopoietic system MP:0005397 9.02 CXCL9 GZMB IFNA1 IFNA2 TIA1

Drugs & Therapeutics for Lymphomatoid Granulomatosis

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
Lenograstim Approved, Investigational Phase 2 135968-09-1
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
Iron Approved Phase 2 7439-89-6 29936
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
Nivolumab Approved Phase 2 946414-94-4
Busulfan Approved, Investigational Phase 2 55-98-1 2478
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
Brentuximab vedotin Approved, Investigational Phase 1, Phase 2 914088-09-8
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
Palifosfamide Investigational Phase 1, Phase 2 31645-39-3 100427
Oblimersen Experimental, Investigational Phase 2 190977-41-4
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
Alvocidib Experimental, Investigational Phase 1, Phase 2 131740-09-5, 146426-40-6 5466794 5287969
35 Cyclosporins Phase 1, Phase 2
36 Antifungal Agents Phase 1, Phase 2
37 Dermatologic Agents Phase 1, Phase 2
38 Folic Acid Antagonists Phase 2
39 Folate Phase 2
40 Vitamin B9 Phase 2
41 Vitamin B Complex Phase 2
42 Protective Agents Phase 2
43 Neuroprotective Agents Phase 2
44 Antiemetics Phase 2
Methylprednisolone Acetate Phase 2 584547
46 Gastrointestinal Agents Phase 2
47 Iron Chelating Agents Phase 2
48 Chelating Agents Phase 2
49 Anti-Asthmatic Agents Phase 2
50 Respiratory System Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
2 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
3 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
4 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
5 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
6 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
7 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
8 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
9 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
10 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
11 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
12 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
13 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
14 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
15 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
16 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
17 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
18 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
19 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
20 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
21 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
22 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
23 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
24 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
25 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2 Rituxan and EPOCH
26 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Active, not recruiting NCT03038672 Phase 2 Varlilumab
27 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Active, not recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
28 Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma Terminated NCT00089076 Phase 1, Phase 2
29 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Terminated NCT01805037 Phase 1, Phase 2 brentuximab vedotin
30 A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma Terminated NCT00112723 Phase 1, Phase 2 alvocidib
31 RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) Terminated NCT01044745 Phase 2 rituximab;mycophenolate mofetil;tacrolimus;anti-thymocyte globulin;cyclophosphamide;fludarabine phosphate;busulfan
32 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
34 A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
35 Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
36 Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies Completed NCT00458731 Phase 1 cediranib maleate
37 Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction Completed NCT00499811 Phase 1 vorinostat
38 A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-B-D-arabinofuranosyl) Uracil, NSC#678515) in Patients With Advanced Solid Tumors Completed NCT00769288 Phase 1 2'-F-ara-deoxyuridine
39 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
40 A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors Completed NCT00891072 Phase 1 R-(-)-gossypol acetic acid;paclitaxel;carboplatin
41 A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
42 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer. Completed NCT00098891 Phase 1 entinostat;isotretinoin
43 A Phase I Pharmacokinetic Study of PS341 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group Completed NCT00054483 Phase 1 bortezomib
44 A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma Completed NCT00348985 Phase 1 belinostat;bortezomib
45 A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies Completed NCT00343798 Phase 1 cyclophosphamide;fludarabine phosphate;cyclosporine;mycophenolate mofetil
46 A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
47 A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies Completed NCT01254578 Phase 1 Lenalidomide
48 Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors Completed NCT01748721 Phase 1
49 A Phase 1 Study of RO4929097 (NSC749225) in Combination With Capecitabine in Refractory Solid Tumors Completed NCT01158274 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;capecitabine
50 A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma Completed NCT00720135 Phase 1

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Interferon Alfa-2b

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.

Genetic Tests for Lymphomatoid Granulomatosis

Anatomical Context for Lymphomatoid Granulomatosis

Organs/tissues related to Lymphomatoid Granulomatosis:

MalaCards : B Cells, Spleen, Liver, Skin, Bone Marrow, T Cells, Bone

Publications for Lymphomatoid Granulomatosis

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 771)
# Title Authors PMID Year
The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. 53 62
9354680 1997
[Lymphomatoid granulomatosis--remission induction with interferon-alpha 2b]. 53 62
9340250 1997
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. 53 62
8639820 1996
Brain PET Imaging of 11C-Methionine, 18F-FDG, and 18F-THK5351 in a Case of Lymphomatoid Granulomatosis. 62
36342805 2022
Rituximab Monotherapy for Grade 2-3 Lymphomatoid Granulomatosis with Central Nervous System Involvement in a Patient Receiving Methotrexate for Rheumatoid Arthritis. 62
36418093 2022
Cutaneous lymphomatoid granulomatosis without other organ involvement developed after long-term treatment with immunosuppressive agents: a case report. 62
36440981 2022
New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. 62
36216980 2022
Two cases of EBV infection preceding lymphoma. 62
35732965 2022
A rare case of pulmonary lymphomatoid granulomatosis that clinically mimics sarcoidosis. 62
36308219 2022
An Update on EBV and HTLV-1 Induced Cutaneous Manifestations. A Review of the Ibero-American Society of Dermatopathology (SILADEPA). CME Part II. 62
36049582 2022
An Update on Viral Induced Cutaneous Lymphoproliferative Disorders. A Review from the Ibero-American Society of Dermatopathology (SILADEPA). CME Part I. 62
36041557 2022
A Case of Lymphomatoid Granulomatosis in a Lymph Node with Unique Clinical and Histopathologic Features. 62
35918872 2022
Pulmonary lymphomatoid granulomatosis in a 4-year-old girl: A case report. 62
35812680 2022
Lymphomatoid granulomatosis in a patient with DOCK8 deficiency. 62
35754125 2022
A Case of Lymphomatoid Granulomatosis Presenting as a Cervical Mass. 62
35494936 2022
Smoldering cutaneous course of lymphomatoid granulomatosis. 62
35198702 2022
Central airway obstruction from lymphomatoid granulomatosis treated with an endobronchial stent. 62
36386282 2022
A rare case of pulmonary lymphomatoid granulomatosis complicated with venous thrombosis. 62
35115745 2022
A Rare Central Nervous System Involvement Due to CTLA-4 Gene Defect. 62
36160072 2022
Primary pulmonary T-cell lymphoma after operation for small intestinal stromal tumor: A case report. 62
36439470 2022
Impact of Epstein-Barr virus infection in patients with inflammatory bowel disease. 62
36389673 2022
Case report: Simultaneous occurrence of primary pulmonary lymphoma and opportunistic infections in a patient with chronic myeloid leukemia. 62
36330481 2022
High-grade Primary Central Nervous System Lymphomatoid Granulomatosis: Successful Rituximab Monotherapy. 62
34121006 2021
Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis. 62
34653948 2021
Lymphomatoid Granulomatosis in HIV-2: A Rare Entity. 62
34984144 2021
A case of lymphomatoid granulomatosis with central nervous system involvement successfully treated with IFNα. 62
34159518 2021
Primary lymphomatoid granulomatosis of the central nervous system: a diagnostic challenge. 62
34229982 2021
The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay. 62
34128135 2021
Light Chain-Restricted Plasmacytoid Cells in Hyperplastic Germinal CentersA Clinicopathologic Investigation. 62
34406351 2021
Cancers associated with human gammaherpesviruses. 62
34536980 2021
[A case of central nervous system primary lymphomatoid granulomatosis with multiple vascular lesions in the spinal cord and brain]. 62
34433742 2021
Lymphomatoid granulomatosis of the central nervous system (CNS-LYG) posing a management challenge. 62
34512987 2021
Pulmonary manifestations of grade III lymphomatoid granulomatosis complicated by haemophagocytic lymphohistiocytosis: Rare disorders. 62
35844674 2021
A case of central nervous system lesion pathologically characterized by angiocentric, T-cell-rich lymphoid cell infiltrates: a case report and literature review. 62
33783654 2021
Pulmonary lymphomatoid granulomatosis: An uncommon disease but not to be forgotten-a single centre experience. 62
34094574 2021
Systematic Review of Spinal Lymphomatoid Granulomatosis Cases. 62
34142079 2021
Lymphomatoid granulomatosis in one patient with newly diagnosed HIV infection and Kaposi's sarcoma: a case report and literature review. 62
33777257 2021
The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis. 62
30826140 2021
Primary central nervous system lymphomatoid granulomatosis: a case report. 62
33083935 2021
Primary Central Nervous System Lymphomatoid Granulomatosis Presenting as Diffuse Corpus Callosum Lesions. 62
33904487 2021
Lymphomatoid granulomatosis: a mimicker of systemic inflammatory rheumatological disease. 62
32669017 2021
Angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat, with cutaneous and ocular metastasis. 62
33568011 2021
EBV Positive Lymphomatoid Granulomatosis Following Dental Extractions. 62
33634720 2021
Chronic lymphocytic infiltration with pontine perivascular enhancement responsive to steroids (CLIPPERS) and its association with Epstein-Barr Virus (EBV)-related lymphomatoid granulomatosis: a case report. 62
33602163 2021
Neuroimages and Neuropathology of a Stroke-Like Cerebral Lymphomatoid Granulomatosis. 62
32624028 2021
Primary Pulmonary B-Cell Lymphoma: A Review and Update. 62
33499258 2021
A case of resected pulmonary lymphomatoid granulomatosis. 62
33437613 2021
Lymphomatoid Granulomatosis Involving the Lung and Brain in a Child: A Case Report. 62
36237476 2021
A rare case of severe right heart failure due to pulmonary artery lymphomatoid granulomatosis. 62
32964628 2020
Primary lymphomatoid granulomatosis of the central nervous system: A diagnostic challenge. 62
33077291 2020

Variations for Lymphomatoid Granulomatosis

Expression for Lymphomatoid Granulomatosis

Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.

Pathways for Lymphomatoid Granulomatosis

Pathways related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 11.29 GZMB CXCL9
3 11.22 IFNA2 IFNA1
4 10.52 IFNA2 CXCL9
5 10.07 IFNA1 CXCL9

GO Terms for Lymphomatoid Granulomatosis

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cellular response to virus GO:0098586 9.8 IFNA2 IFNA1
2 defense response to virus GO:0051607 9.8 IFNA2 IFNA1 CXCL9
3 negative regulation of translation GO:0017148 9.78 TIA1 GZMB
4 humoral immune response GO:0006959 9.76 IFNA2 IFNA1
5 B cell proliferation GO:0042100 9.73 IFNA2 IFNA1
6 type I interferon-mediated signaling pathway GO:0060337 9.71 IFNA2 IFNA1
7 response to exogenous dsRNA GO:0043330 9.67 IFNA1 IFNA2
8 T cell activation involved in immune response GO:0002286 9.56 IFNA2 IFNA1
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.46 IFNA2 IFNA1
10 natural killer cell activation involved in immune response GO:0002323 9.26 IFNA2 IFNA1
11 defense response GO:0006952 8.92 IFNA2 IFNA1 CXCL9

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.63 IFNA2 IFNA1 CXCL9
2 cytokine receptor binding GO:0005126 8.96 IFNA2 IFNA1
3 type I interferon receptor binding GO:0005132 8.92 IFNA2 IFNA1

Sources for Lymphomatoid Granulomatosis

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....